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Abstract
Introduction: Pre-injury antithrombotic therapy might influence the outcome of subjects with head injuries and
positive computed tomography (CT) scans. We aimed to determine the potential risk of pre-injury antiplatelet drug
use on short- and long-term outcome of head injured subjects admitted to emergency departments (EDs) in Italy
for extended observation.
Methods: A total of 1,558 adult subjects with mild, moderate and severe head injury admitted to Italian EDs were
studied. In multivariable logistic regression analyses, the short-term outcome was assessed by an evaluation of
head CT scan at 6 to 24 hours after trauma and the long-term outcome by the Glasgow outcome scale (GOS) at
six months.
Results: Head CT scan comparisons showed that 201 subjects (12.9%) worsened. The risk of worsening was
increased two fold by the use of antiplatelet drugs (106, 19.7% treated versus 95, 9.3% untreated; relative risk (RR)
2.09, 95% CI 1.63 to 2.71). The risk was particularly high in subjects on clopidogrel (RR 5.76, 95% CI 3.88 to 8.54),
independent of the association with aspirin. By logistic regression, 5 of 14 items were independently associated
with worsening (Glasgow coma scale (GCS), Marshall category, antiplatelet therapy, intraventricular hemorrhage,
number of lesions). After six months, only 4 of 14 items were predictors of unfavorable outcome (GOS 1 to 3) (GCS
score, Marshall category, age in decades, intracerebral hemorrhage/contusion). The risk increased by 50% in the
group treated with antiplatelet therapy (RR 1.58, 95% CI 1.28 to 1.95; P < 0.001).
Conclusions: Antithrombotic therapy (in particular clopidogrel) is a risk factor for both short-term and long-term
unfavorable outcome in subjects with head injury, increasing the risk of progression and death, permanent
vegetative state and severe disability.
Introduction
Subjects admitted to the emergency department (ED)
with intracranial lesions following head injury are a spe-
cial challenge for emergency physicians. They represent
a heterogeneous group of patients with large variability
as to injury severity, clinical course, neurological recov-
ery and overall outcome [1].
Worsening detected by imaging and clinical deteriora-
tion are associated with an unfavorable outcome, and a
group of predictor variables has been related to worsen-
ing-type lesions and future events [2-4]. In a few cases,
progression is extremely rapid and the ultimate outcome
might be unfavorable because of delayed transfer to neuro-
surgical units; in other cases the lesions do not progress
and the final outcome is usually favorable.
In the last decade the use of antithrombotic therapy with
antiplatelet drugs has grown considerably, as an effect of
national and international guidelines promoting their
widespread use to prevent cardiovascular events in high-
risk populations and particularly in older people [5,6]. In
the same period, the epidemiology of the trauma popula-
tion has also changed, with a larger and larger prevalence
of older age-groups [7], where antiplatelet drug use is
more prevalent, in the presence of comorbidities [8,9].
The aim of this study was to test the effect of pre-injury
antiplatelet therapy on short- and long-term outcomes in
subjects with head injury and a positive computed tomo-
graphy (CT) scan at first evaluation.
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Methods
Study design and settings
This multicenter observational study included all adult
subjects, who attended 32 Italian EDs of community and
regional hospitals for mild, moderate or severe head injury
and intracranial lesions within 24 hours from the event
(from January to December 2009). The participating cen-
ters represented a wide variety of facilities, distributed
across the country, to increase external validity and to
make the results generalizable to the majority of subjects
observed for head injury. The centers included hospitals
with neurosurgical units, hospitals with teleradiology-
consulting systems connected with a neurosurgical center
and hospitals without neurosurgical and teleradiology
facilities.
Adult subjects ≥ 18 years old with mild (Glasgow
coma scale (GCS) = 15 to 14) or moderate to severe
(GCS ≤ 13) head injury within 24 hours of trauma and a
positive head CT scan at their first evaluation in the ED
were included in the study. The subjects were all conse-
cutive patients with a positive head CT scan without
indication of urgent (within 7 days) neurosurgical hema-
toma/hemorrhage evacuation (Marshall category 2 to 4
at entry).
Excluded were subjects in the presence of: a) an initial
head CT scan requiring urgent neurosurgical interven-
tion (Marshall category 5) or not-operated mass lesion
(Marshall 6 category); b) GCS = 3 and bilateral, fixed and
dilated pupils; c) an unclear history of the mechanism of
injury as the primary event; d) hypotension, that is, systo-
lic blood pressure persistently < 90 mmHg during the
observation period; e) the need for cardiopulmonary
resuscitation; f) penetrating injuries at presentation; and
g) discharge against medical advice.
The use of antiplatelet drugs was systematically
recorded, independent of time of exposure. Aspirin
(usual dose, 100 mg), ticlopidine, indobufen (a popular
antithrombotic drug used in Italy) and clopidogrel were
considered, as well as the potential antiplatelet activity
of other anti-inflammatory agents. During the observa-
tion period there was no specific indication for rescue
therapy with human prothrombin complex or platelet
transfusions in subjects treated with anticoagulant/anti-
platelet agents, and no patients received this support
treatment.
Treatment protocol
From the ED, subjects were transferred for observation
and treatment to a high dependency unit, ordinary
admitting unit, neurosurgical unit or ICUs. After
admission, all patients were submitted to additional
head CT scan within 6 to 24 hours from injury accord-
ing to local protocols. Furthermore, CT was always
repeated in the case of clinical or neurological
deterioration. The time interval between trauma and
the initial head CT scan was dictated by emergency
procedures of the individual centers. For the purpose
of the present study, all head CT scans were retrospec-
tively reviewed in a temporal sequence by an indepen-
dent expert neuroradiologist in a blinded fashion to
confirm the initial diagnosis and to evaluate possible
worsening in the head CT scan at 6 to 24 hours.
CT scans were classified according to the criteria of
Marshall [10], modified according to the revision of the
European Brain Injury Consortium (EBIC) [11].
The protocol was carried out according to the Hel-
sinki Declaration and approved by the ethical committee
of the Local Health District of Forlì. All data were trans-
ferred from the peripheral centers to the coordinating
unit in a completely anonymous form. According to the
Italian law on privacy protection and use of personal
data (Dls n. 85, March 1, 2012), informed consent is not
needed whenever handling is carried out in an anon-
ymous form on retrospective data on file and it would
be technically impossible to trace people for signing
consent forms.
Variables definition
A few items were selected as the variables potentially
associated with outcomes. We considered age, sex, type
of injury (motor vehicle accidents, falls or accidental,
work-related, assault, sport injuries and other causes),
coagulation (by prothrombin time) and neurological sta-
tus (by GCS), as well as the use of antithrombotic
agents as described above. In the antiplatelet group, we
also considered the few cases in which other non-steroi-
dal anti-inflammatory drugs (NSAIDs) with a definite
antiplatelet activity had been administered in the three
days before trauma for other reasons.
Comorbidities, although common and associated with
outcome in spontaneous intracerebral hemorrhage [8,9],
were not considered in the present analysis. In previous
studies on traumatic brain injury comorbidities did not
predict short- or long-term outcome [1].
The intracranial injuries considered for analyses were:
traumatic subarachnoid hemorrhage (t-SAH), subdural
hematoma (SDH), epidural hematoma (EDH), intracereb-
ral hemorrhage/contusion (ICH) or depressed skull frac-
ture (DSF) and intraventricular hemorrhage (IVH)
[12,13]. IVH was considered a distinctive intracranial
injury, but no subjects were considered with positive
head CT scans for this type of injury as a unique lesion.
In all cases IVH resulted in different combinations with
other types of intracranial injury.
Patients’ coagulation status (prothrombin time) was
determined by protocol in all cases. Values of the Inter-
national Normalized Ratio (INR) > 1.5 were considered
at risk of hemorrhage.
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Outcome measures
Short-term outcome measures were: a) intracerebral
injuries with worsening characteristics, indicated by a
change of at least one point in Marshall category
between initial and follow-up CT scan performed during
serial controls within 24 hours; and b) the need for neu-
rosurgical intervention because of clinical and/or radi-
ological deterioration during the observation period.
This period was limited to the first seven days after
diagnosis in order to exclude delayed complication of
injury (chronic subdural hematomas, hygromas or
hydrocephalus) [12].
As a long-term outcome measure we considered the
Glasgow outcome scale (GOS) at six months. For ease of
analysis and reporting, the five-point GOS score was cate-
gorized as either favorable (moderate disability or good
recovery - GOS 4 to 5) or unfavorable (dead, vegetative, or
severely disabled - GOS 1 to 3). The follow-up GOS was
rated by an expert physician unaware of the study proto-
col, on the basis of the response to a structured telephone
call [12]. Main outcome measures were then related to the
different hospital facilities, for example, hospital with neu-
rosurgical unit, hospital with telemedicine consultation
only (no neurosurgical unit) and hospital without both
neurosurgical unit and telemedicine consultation.
Statistical analysis
A data mining method was chosen to select relevant pat-
terns between predictor variables and main outcomes by
Weka software (University of Waikato, Hamilton, NZ).
We used a decision tree technique, in which nodes indi-
cate decision points, chance events, or branch terminals.
Branches correspond to each decision alternative or event
outcome emerging from a node. The root nodes are the
first set of decision alternativeness. The construction of a
decision tree was obtained by a ‘recursive partitioning’
analysis [14].
Mean value, SD and frequencies were used to describe
data distribution. We used multivariable logistic regres-
sion analysis with a P value greater than 0.05 for removal
of variables. A score for the risk of unfavorable outcome
was calculated for each patient on the basis of the coeffi-
cients computed by the logistic regression derived from
variables entering the stepwise procedure. The accuracy
of the risk score was then evaluated by the area under
the receiver operating characteristic (ROC) curves. The
odds ratio (OR) and 95% CI were also calculated. We
tested the association of each variable with the primary
outcome measure using Chi-square tests for nominal
variables, the Mann-Whitney U test for ordinal variables,
and the unpaired two-tailed t-test for continuous vari-
ables (SPSS software, version 17.0 - SPSS Inc., Chicago,




The mean age of the 1,558 subjects with intracranial
lesions was 65 years (SD 21), with 288 (18.5%) patients
under 40 and 664 subjects (42.6%) over 75. The vast
majority of subjects (1,123 cases, 72.1%) had a mild
head injury with GCS 14 to 15, 420 cases (24.9%) had a
moderate injury (360 cases with GCS 13 to 11 and 60
with GCS 10 to 9). The last group of 15 subjects (1.0%)
had a Marshall category 2 to 4 and severe head injury
(GCS < 9) (Table 1).
A total of 708 subjects (45.4%) were injured by falls or
accidents with 474 (30.4%) following a road accident. In
the remaining subjects the head injury was work-related
(83 cases, 5.3%) or following an assault (46, 3.0%), or
related to sports and other causes (247, 15.8%) (Table 1).
At the first evaluation, 1,328 subjects (85.2%) had an
intracranial injury with Marshall category 2, 168 subjects
(10.8%) had category 3, and only 62 cases (4.0%) had cate-
gory 4 (Table 1). A single lesion was recorded in 886 sub-
jects (56.9%), 2 lesions in 430 cases (27.6%) and 3 or more
lesions in the remaining 237 cases (15.2%). The frequency
distribution of type of lesion was: ICH (766 cases; 49.2%),
SDH (604; 38.8%), t-SAH (776; 49.8%), EDH (157; 10.1%)
and IVH (94; 6.0%) (Table 1).
Pre-injury antiplatelet therapy was recorded in 537
subjects (34.5%) of the entire cohort (454, 49.1% in the
group ≥ 65 years old). Aspirin was the most frequently
used antiplatelet medication (439 subjects, 28.2%), fol-
lowed by ticlopidine (69, 4.4%), clopidogrel (28, 1.8%),
NSAIDs (20, 1.3%) and low molecular weight heparin
(10, 0.6%). A group of 129 cases (8.3%) had INR > 1.5
because of simultaneous treatment with warfarin.
Outcome prediction
Short-term outcome
In 201/1,558 subjects (12.9%) head CT scan comparison
documented a worsening lesion in the short-term. Anti-
platelet therapy increased the risk of worsening two-fold
(n = 106, 19.7% of treated versus 95, 9.4% of untreated
cases), corresponding to a relative risk (RR) of 2.09, 95%
CI 1.63 to 2.71 (Figure 1). Compared with untreated
subjects, the risk was particularly high in subjects on
clopidogrel (RR 5.76, 95% CI 3.88 to 8.54), independent
of the association with aspirin (15 cases, 8 with worsen-
ing lesions; RR 5.73, 95% CI 3.44 to 9.55; P < 0.001).
On multivariable logistic regression analysis a group of
5/14 items was independently associated with worsening
lesion (Table 2). The discriminating operating character-
istics area of the selected items was 0.777 (95% CI 0.755
to 0.797; P < 0.001).
Data mining analysis selected the following relevant
patterns between predictor variables and main out-
comes: a) in subjects with mild head injury (GCS 15 to
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14), antiplatelet therapy increased the risk of worsening
two-fold when the number of lesions at the first CT
scan was ≤ 2, (6.90% treated versus 3.70% not treated;
RR 1.86, 95% CI 1.06 to 3.30, P = 0.032) and further
increased the risk of worsening when the number of
lesions was ≥ 3 (34.8% treated versus 10.4% not treated;
RR 3.34, 95% CI 1.74 to 6.40, P = 0.003) (Figure 2); b)
in subjects with moderate-severe head injury antiplatelet
therapy increased the risk of worsening when the num-
ber of lesions at the first CT scan was ≤ 2 (37.6% trea-
ted versus 21.8% not treated, RR 1.72, 95% CI 1.21 to
2.45; P = 0.002 (Figure 2).






OR (95% CI) P value
Sex (males) 125 (62.2%) 786 (57.9%) 1.19 (0.88 to1.62) 0.283
Age (mean: SD) 65 (22) 65 (21) – –
Mechanism of Injury
Road accident 60 (29.9%) 414 (30.5%) 0.97 (0.70 to 1.34) 0.870
Other causes 86 (42.8%) 622 (45.8%) Reference –
Glasgow Coma Scale
Moderate-Severe (≤ 13) 127 (63.2%) 308 (22.7%) 5.84 (4.27 to 8.00) < 0.001
Mild (15 to 14) 74 (36.8%) 1.049 (77.3%) Reference –
Basal skull fracture 28 (13.9%) 117 (8.6%) 1.71 (1.10 to 2.67) 0.019
Type of lesion
Subdural hematoma 106 (52.7%) 498 (36.7%) 1.92 (1.43 to 2.59) < 0.001
Epidural hematoma 28 (13.9%) 129 (9.5%) 1.54 (0.99 to 2.39) 0.059
Intracerebral hemorrhage/contusion 116 (57.7%) 650 (47.9%) 1.48 (1.10 to 2.0) 0.010
Traumatic subarachnoid hemorrhage 105 (52.2%) 671 (49.4%) 1.12 (0.83 to 1.50) 0.497
Intraventricular hemorrhage 10 (4.9%) 84 (6.2%) 0.79 (0.40 to 1.55) 0.634
Depressed skull fracture 25 (12.4%) 116 (8.5%) 1.52 (0.96 to 2.41) 0.086
Anticoagulant therapy 18 (9.0%) 108 (8.0%) 1.14 (0.68 to 1.92) 0.582
Antiplatelet therapy 106 (52.7%) 431 (31.8%) 2.40 (1.78 to 3.23) < 0.001
Data are reported as number of cases and %, or median and standard deviation; SD.
Antiplatelet Therapy  
537 (34.5%)  
No Therapy 




 106 (19.7%)  
Stable/Improved 
 431 (80.3%)  
Worsening 
 96 (9.4%)  
Stable/Improved 
 925 (90.6%)  
Figure 1 Distribution of worsening events in relation to antiplatelet therapy in subjects with intracranial lesions following head injury.
Significant outcomes in the decision tree analysis are reported as white text on a grey background.
Fabbri et al. Critical Care 2013, 17:R53
http://ccforum.com/content/17/2/R53
Page 4 of 11
Worsening seen on serial CT scans resulted in neuro-
surgical intervention in 46 subjects (2.9%). The interven-
tion was required for EDH (8 cases), SDH (30 cases)
and ICH (8 cases). Neurosurgical intervention was
needed more frequently in subjects treated with antipla-
telet drugs (21.2% treated versus 11.2% untreated, RR
1.90, 95% CI 1.35 to 2.66; P < 0.001). On multivariable
logistic regression analysis 8/15 items (male sex, younger
age, mechanism of injury, INR > 1.5, antiplatelet ther-
apy, GCS, Marshall category, and type of lesions) were
independently associated with worsening and the need
for neurosurgical intervention.
Long-term outcome
A complete six-month follow-up was obtained in 1,222/
1,558 subjects (78.4%). A total of 336 cases (21.6%) were
lost at follow up and in 115 (7.4%) cases GOS was unre-
liable due to previous disability or trauma-related dis-
ability not dependent on head injury.
Outcome was unfavorable in 78 cases (5.0%): 26
patients (1.7%) died during the six-month follow up, 9
patients (0.6%) were judged in a permanent vegetative
state and 43 (2.8%) were severely disabled. The majority
of subjects (n = 1,144, 73.4%) had a favorable outcome,
with moderate disability being present in only 168 cases
(10.8%). At follow up, the risk of unfavorable outcome at
six months increased by 50% in the group treated with
antiplatelet therapy (9.7% treated versus 4.4% untreated;
RR 1.58, 95% CI 1.28 to 1.95; P < 0.001) (Figure 3).
On multivariable logistic regression analysis only 4/14
items (GCS, Marshall severity, age in decades, intracer-
ebral hemorrhage/contusion) were selected as predictors
of unfavorable outcome (Table 3). The discriminating
operating characteristics area of the selected items was
0.891 (95% CI 0.860 to 0.921); P < 0.001.
These results were confirmed by ordinal regression
analysis: five items (Marshall severity, GCS, age in dec-
ades, antiplatelet therapy and type of injury) were
selected for the prediction of GOS with a discriminating
operating characteristics area of 0.716 (95% CI 0.645 to
0.786; P < 0.001).
These results were not significantly different after
exclusion of subjects treated with warfarin or low mole-
cular weight heparin (LMWH) (discriminating operating
characteristics area of 0.783 (95% CI 0.746 to 0.820; P <
0.001)) and in the subgroup of subjects fully recovered
or with moderate disability at six months, that is, GOS
4 to 5 (0.716, 95% CI 0.645 to 0.786; P < 0.001).
Data mining analysis did not select any relevant pat-
tern in relation to different hospital facilities, that is,
neurosurgery versus telemedicine systems versus none;
P test for trend = 0.144).
Discussion
This observational study derived from Italian EDs
shows that pre-injury antithrombotic therapy is asso-
ciated with negative outcomes in subjects with head
injury and intracranial lesions with an indication of
observation and conservative treatment; in the short-
term progression of lesions was seen on the CT scan,
in the long-term the risk of unfavorable outcome
increased. The risk of lesion worsening was particularly
high when subjects were treated with clopidogrel, inde-
pendent of the concomitant use of other antiplatelet
agents.
Table 2 Logistic model of variables considered in predicting subjects with worsening lesions after head injury
Covariates Odds Ratio 95% CI P value
Sex (males) 1.24 0.88 to 1.75 0.211
Age (decades) 0.91 0.83 to 1.01 0.065
Road accidents 1.03 0.70 to 1.52 0.874
Glasgow Coma Scale 4.59 3.23 to 6.51 < 0.001
Basal skull fracture 1.20 0.72 to 1.99 0.480
Marshall category 1.43 1.09 to- 1.89 0.011
Type of lesion
Subdural hematoma 1.32 0.86 to 2.01 0.205
Epidural hematoma 1.13 0.65 to 1.98 0.656
Intracerebral hemorrhage/contusion 0.96 0.62 to 1.50 0.875
Traumatic subarachnoid hemorrhage 0.80 0.51 to 1.24 0.322
Intraventricular hemorrhage 0.37 0.17 to0.775 0.008
Depressed skull fracture 1.03 0.60 to 1.78 0.903
Number of lesions (≥ 2) 2.56 1.46 to 4.51 0.001
Anticoagulant therapy 1.17 0.65 to 2.10 0.606
Antiplatelet therapy 2.87 1.94 to 4.23 < 0.001
Marshall category (category 2-3-4) and age (decades) were considered as continuous variables, Glasgow Coma scale for categories (mild and moderate-severe;
the lower score the higher risk). The remaining variables were dichotomized.
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Mild Head Injury 
1.123 (72.1%)  
Total cases 
1.558  
≤ 2 Lesions  
952 (61.1%)  
≤ 2 Lesions  
315 (20.2%)  
≥3 Lesions 
171 (11.0%)  
Moderate-Severe 
Head Injury  
420 (6.7%) 
Worsening 
38 (21.8%)  
No Therapy 
 174 (55.2%)  
Antiplatelets 
141 (44.8%)  
Worsening 
13 (10.4%)  
Antiplatelets 
 304 (31.9%)  
No Therapy 
 648 (68.1%)  
Antiplatelets  
85 (31.6%)  
No Therapy 
 125 (73.1%)  
Worsening 
 29 (34.1%)  
Worsening 
 24 (3.7%)  
Worsening 
 21 (6.9%)  
Worsening 
53 (37.6%)  
≥3 Lesions 
105 (6.7%)  
Worsening 
15 (22.7%)  
No Therapy 
 66 (62.8%)  
Antiplatelets 
39 (37.1%)  
Worsening 
13 (33.3%)  
 
Figure 2 Data mining analysis: relevant patterns of variables predicting cases with worsening lesions in relation to severity of head
injury (mild versus moderate-severe head injury), number of intracranial lesions and antiplatelet therapy. Significant variables are
reported as white text on a grey background.
Favourable Outcome  




 409 (35.7%)  
No Therapy 
 735 (64.2%)  
Antiplatelets 
 44 (56.4%)  
No therapy 
 34 (43.6%)  
Unfavourable Outcome 
 78 (6.4%)  
Figure 3 Unfavorable outcomes in subjects with head injury and intracranial lesions in relation to antiplatelet therapy. Significant
outcomes are reported as white text on a grey background.
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The prognosis of subjects with head injury and intra-
cranial lesions with an indication for conservative treat-
ment is extremely variable, depending on the progression
of injury, the size of the lesion and secondary injury
responses that may worsen the primary lesion [15]. The
earlier the initial CT scan, the greater the likelihood that
the lesions will progress at follow-up. Progression gener-
ally occurs within the first 12 hours, but may occur as
late as three to four days after trauma. Small contusions
that progress are usually clinically silent and are less
likely to require neurosurgical intervention [16], whereas
large contusions in subjects with low GCS scores are
more likely to evolve [15].
Injury progression was defined by worsening of the Mar-
shall category, a validated tool to assess the outcome of
subjects with head injury [17-19]. According to EBIC [11],
an increase in the Marshall CT category at the follow-up
CT scan may be considered a sign of disease progression.
Whenever the initial CT scan shows a diffuse injury with-
out swelling or shift worsening to a mass lesion with need
of neurosurgical intervention, the outcome becomes defi-
nitely unfavorable (62% versus 38%) [20].
Our data confirmed that the risk of imaging progres-
sion is associated with the severity of the initial Marshall
category with 10.2% of cases worsening in the group of
subjects classified as Marshall category 2, 25.6% of sub-
jects in category 3 and 37.1% of subjects categorized as
Marshall 4. Our worsening rate is, however, much lower
than that reported in different series from neurosurgical
facilities, where approximately 50% of patients with
lesions who were admitted for conservative treatment
showed progression [21-24]. This difference is probably
due to the selection of more severe and younger patients
in neurosurgical units, including Marshall 5 cases, com-
pared to those observed in a general ED. This hypothesis
is also confirmed by a larger use of neurosurgical evacua-
tion reported in those settings, whereas neurosurgery
may be contraindicated in older persons, although this
issue is not settled.
A group of variables (injury severity, anticoagulant ther-
apy, need for cardiopulmonary resuscitation in the field,
older age, short duration between injury and the first CT
scan, multiple lesions, midline shift and injuries with need
of neurosurgical procedures) had been indicated as predic-
tors of radiological progression [22,23,25,26]. Our study
confirms the importance of clinical and radiological items
selected by previous studies in predicting lesions likely to
evolve after head injury and indicates antiplatelet therapy
as a relevant, additional predictor.
The negative effect of antiplatelet therapy might
depend on a number of factors, such as minimum con-
tinued bleeding or a microvascular dysfuntion, exagger-
ated by reduced platelet function, favoring edema and
brain swelling, producing a midline shift [15].
We defined progression on the basis of the Marshall
classification. Differences in radiological progression may
depend on the criteria used: 100% [26], 30% [21] or 25%
increase [22] in hematoma dimension, but different cuts
and angulation may introduce an important bias with the
use of strict criteria, such as a 25% to 30% enlargement
[11]. The Marshall category, although crude, provides a
very easy-to-define clinical index of progression. It was
selected as an outcome measure in the short term and,
combined with GCS, it was the only variable associated
with unfavorable outcome at six months, confirming the
clinical importance of this item.
Table 3 Logistic model of variables considered in predicting unfavorable outcome in subjects with head injury
Covariates Odds Ratio 95% CI P value
Sex (males) 1.30 0.75 to 2.26 0.348
Age (decades) 1.33 1.11 to 1.59 0.002
Road accidents 0.85 0.42 to 1.70 0.641
Glasgow Coma Scale 12.94 6.26 to 26.78 < 0.001
Basal skull fracture 0.87 0.35 to 2.12 0.754
Marshall category 3.03 2.09 to 4.39 < 0.001
Type of lesion
Subdural hematoma 0.57 2.78 to 1.16 0.119
Epidural hematoma 0.78 0.31 to 2.00 0.607
Intracerebral hemorrhage/contusion 0.46 0.22 to 0.94 0.034
Traumatic subarachnoid hemorrhage 0.76 0.36 to 1.62 0.481
Intraventricular hemorrhage 2.07 0.86 to 4.96 0.104
Depressed skull fracture 0.75 0.25 to 2.24 0.608
Number of lesions (≥ 2) 1.99 0.77 to 5.10 0.153
Anticoagulant therapy 1.01 0.44 to 2.32 0.971
Antiplatelet therapy 1.02 0.57 to 1.84 0.938
Marshall category (category 2-3-4) and age (decades) were considered as continuous variables, Glasgow Coma scale for categories (mild and moderate-severe;
the lower score the higher risk). The remaining variables were dichotomized.
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Among antiplatelet agents both aspirin and, particu-
larly, clopidogrel increased the risk of evolving lesions,
but their combined use did not further increase the risk.
By contrast, ticlopidine, largely used in Italy in the past,
did not increase the risk. The risk associated with clopi-
dogrel is of particular concern, considering its increasing
use. The advantages of clopidogrel on cardiovascular out-
comes have made it a lifesaving drug in subjects over 45
years old who have cardiovascular disease [5,27]. Its use
was later extended from coronary artery disease to cere-
brovascular and peripheral artery disease, thus being
largely diffused in the elderly population [28]. An analysis
of drug prescriptions in more than 300,000 Italian sub-
jects with diabetes showed an increased prevalence of
antiplatelet drug use from 15% to 52% in the period 1997
to 2006 [29], and in 2008 more than 4% of the general
Italian population was treated with aspirin [30]. In our
series, approximately 35% of the subjects were being trea-
ted with antiplatelet agents, and this figure increased to
53% in the group of subjects more than 75 years old. The
use of these drugs is likely to increase further in the
future, following guidelines indicating antiplatelet drug
therapy in a large proportion of older subjects [5,27].
Two recent reviews have summarized the available evi-
dence on the risk of unfavorable outcomes of antiplatelet
medications, especially in subjects with severe head injury
and older age. Beynon et al. [31], on the basis of the
scarce available evidence, concluded that these agents
increase the risk of an unfavorable outcome, particularly
in cases of severe traumatic brain injury. In a meta-analy-
sis of five studies, Batchelor and Grayson compared the
mortality rates of patients with blunt head trauma who
were on aspirin or clopidogrel versus cases not on anti-
platelet agents [32]. They found a significant heterogene-
ity and a moderately increased overall risk of death for
both drugs, which did not reach statistical significance.
However, the low number of events precludes any firm
conclusion and further work is required.
Event rates constitute an even more significant draw-
back in studies on mild-to-moderate brain injury. None-
theless, the mortality rate of subjects receiving aspirin was
also reported to be higher than normal [33]. In cases
observed in EDs, pre-injury antiplatelet therapy was
recently shown to increase significantly the risk of intra-
cranial lesions in subjects after mild head injury [34],
whereas in a prospective study of mild and moderate head
injury in subjects more than 60 years old, low-dose aspirin
prophylaxis had no effect on the frequency or types of
intracerebral or meningeal hemorrhage [35]. The initial
size of the contusion and the presence of SDH were
selected as predictors of radiological progression, and the
initial GCS and younger age as predictors of good disposi-
tion at discharge [34], but much more evidence is required
before a firm conclusion can be drawn. Anticoagulation
and antiplatelet therapy were not included in any study
model [21].
Age represents an important issue in head injured
patients. In Italy, age is not formally considered a criterion
for admitting patients to hospitals with different levels of
care, but in clinical practice older patients frequently have
limited access to conservative observation in neurosurgical
units and to interventions. Our analysis selected older age
as a significant, independent predictor of long-term out-
come. In the Italian database, 924 subjects (59.3%) were ≥
65 years old and 42% were older than 75, a figure comple-
tely different from previously published studies. In a
widely cited study [36], subjects older than 65 years were
excluded from the analyses, the median age of subjects
was 33 when treated in neurosurgical units and 31 in
those admitted to non-neurosurgical centers. Our database
reflects the ‘real world’ of head injury subjects with
Marshall 2 to 4, observed in the Italian EDs, with a median
age of 72 years and with 30% of the cases older than 80, as
previously reported [37,38].
The growing elderly population and the expanding
indications for anticoagulant therapy might produce
more complications associated with anticoagulant treat-
ment, challenging the emergency physicians more and
more. A very recent study showed that oral anticoagu-
lants may also be safely used in older patients at risk of
fall [39], but in a previous report we showed that antic-
oagulation increased the risk of intracranial lesions by
more than four times, independent of other variables
[12]. In the present study, anticoagulant treatment did
not significantly predict worsening in the 126 cases
(8.1%) on anticoagulants with an INR above 1.5, but a
selection bias may be operative. In subjects on oral
anticoagulants, the initial lesion might be so severe (that
is, Marshall 5 or 6) that is excludes them from the ana-
lysis. The progressive use of rapid anticoagulation rever-
sal will clarify this problem.
A few limits should be considered. Firstly, selection
biases might be present because of the retrospective nat-
ure of the analysis of clinical records and different extrac-
tion procedures according to software available in the
various EDs. These biases might be amplified by incom-
plete recording of drug use and/or incomplete reporting
by patients. Underreporting of drug use might also
increase in relation to incomplete anamnesis by physi-
cians, unaware of the possible risk associated with anti-
platelet drugs.
Secondly, the time lag between head trauma and CT
scanning was variable between a few hours to 24 hours.
Both trauma-to-admission and admission-to-CT times
were variable, according to clinical judgment, with an
influence on the natural history of lesions. As discussed
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above, these biases might be reduced by the use of the
Marshall classification, in which category changes imply
evident changes in the imaging appearance of lesions.
Thirdly, the history of antiplatelet drug use might be
completed by the analysis of antiplatelet activity. In a
series of 84 subjects treated with aspirin, 2.4% of cases
had normal platelet function, and 42% of subjects with-
out a documented history of aspirin use had platelet
inhibition. Aspirin resistance is a multifactorial phenom-
enon, associated with comorbidities, leading to reduced
platelet activation and aggregation [40,41]. However,
aspirin history and the measured activity of platelet inhi-
bition were associated with only a marginal risk of CT
scan progression, craniotomy, mortality or poor out-
come at multivariable analysis [42].
Fourthly, we did not consider comorbidities in our
analysis. Comorbidities have a definite importance in
hemorrhagic stroke [8] and spontaneous intracerebral
hemorrhage [9], whereas their importance in traumatic
lesions is doubtful. The use of antiplatelet drugs might
identify subjects with more prevalent cardiovascular dis-
ease, at higher risk of spontaneous cerebro-vascular
events, independent of antiplatelet use. Apparently, this
does not apply to traumatic brain lesions and the Charl-
son index of comorbidities was not associated with out-
come in a previous study in Italian EDs [1,2].
Finally, an increase in the Marshall CT classification
score would not always represent lesion extension or
disease progression. The hierarchy of Marshall class is
based on the absence/presence of signs of raised intra-
cranial pressure, such as brain swelling, midline shift
and mass lesions which need neurosurgiucal evacuation.
This is very likely to determine an unfavorable outcome
in the long term, but this is not always the case. Lack of
significance of variables other than Marshall category
and GCS versus outcome determined by GOS categories
does not exclude possible clinical relevance.
Conclusions
Our data, which are derived from a representative num-
ber of Italian EDs, show that pre-injury antithrombotic
therapy is associated with an increased risk of short-
term radiological worsening and six-month unfavorable
outcome in subjects with a positive head CT scan, parti-
cularly in subjects treated by clopidogrel. The results
should be considered in predictive algorithms of future
guidelines of diagnosis and treatment of head injury.
Key messages
• In subjects with mild or moderate-severe head injury
and a positive head CT scan with indications for conser-
vative treatment, 12.9% of subjects worsened by CT
comparison (change of at least one point in the Marshall
category) at 6 to 24 hours.
• A group of 5/14 items (GOS, Marshall category,
antiplatelet therapy, IVH, number of lesions) were inde-
pendently associated with short term (6 to 24 hours)
worsening.
• Pre-injury antiplatelet therapy increased the risk of
short term worsening two-fold. The risk was particularly
high in subjects on clopidogrel, independen of the asso-
ciation with other antiplatelet drugs.
• At long-term follow up (six months), only 4/14
items (GCS, Marshall severity, age in decades, intracer-
ebral hemorrhage/contusion) were selected as predictors
of unfavorable outcome. The risk increased by 50% in
the group treated with antiplatelet therapy.
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